PROM1 and melanoma: The CD133+ and ABCB5+ MSLCs in perivascular niches, expressing VE-cadherin, TIE2, VEGF, and VEGFR, possess the ability to acquire the VM phenotype and contribute to melanoma drug resistance [322, 327].